The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Dihexa

N-hexanoic-Tyr-Ile-(6) aminohexanoic amide

C
Animal replicated
Research chemicalAngiotensin IV DerivativeModified OligopeptideHGF/c-Met Modulator
RouteOralGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide — Angiotensin IV Derivative — Angiotensin IV Derivative, Modified Oligopeptide, HGF/c-Met Modulator.
Why people use it
Scopolamine Amnesia Reversal · Aged Rat Cognitive Improvement · APP/PS1 Mouse Model · TBI Working Memory · Healthy Adult Cognitive Enhancement
What the evidence supports
Zero. No human clinical trial of Dihexa itself has been registered or completed. Fosgonimeton (the prodrug) has Phase 2 data showing failure on primary/secondary endpoints. The community uses Dihexa based entirely on rodent behavioral data and mechanistic claims — some of which carry a research integrity shadow.
If you only read one thing

Dihexa attracted more community excitement than almost any nootropic peptide in recent years — the '10 million times more potent than BDNF' claim, the synaptogenesis mechanism, the oral bioavailability, the idea of literally building new synapses rather than just modulating neurotransmitters. The central tension is that the research generating the most exciting claims came from a lab whose foundational mechanistic data has been formally implicated in research misconduct, the CEO who built the company on that research resigned over image manipulation, the federal government was paid $4 million in settlement, and the clinical prodrug failed Phase 2/3. The behavioral rodent data may be valid. Some independent replication exists. The mechanism remains biologically plausible. And the community is using a compound whose scientific foundation has been specifically and formally damaged.

Check interactions →
Route / form

Same compound, route-specific context. Switch forms instead of opening separate pages.

Evidence fit
Route-specific

Use the route notes below to match form, goal, and evidence quality.

Route caveat
Protocol not standardized

No route-matched protocol rows were parsed for this form; use the route notes and full dosing chapter before comparing options.

Protocol anchor
Full dosing section

Open the full report at the dosing chapter for protocol rows, cycle context, and administration notes.

Typical dose snapshot
See route notes
Evidence varies by use case
Published literature
0human trials0human studies3animal2in vitro

No human clinical trial of Dihexa itself; fosgonimeton prodrug trial data should not render as Dihexa human evidence.

Evidence reality check
Human evidence
No human studies
0 observational; RCT evidence not present in corpus.
Preclinical base
5 lab signals
3 animal; 2 in-vitro/mechanistic.
Evidence snapshot
Zero. No human clinical trial of Dihexa itself has been registered or completed. Fosgonimeton (the prodrug) has Phase 2 data showing failure on primary/secondary endpoints. The community uses Dihexa based entirely on rodent behavioral data and mechanistic claims — some of which carry a research integrity shadow.
From the chapter quick-reference block.
Indication map
Supported / plausible / speculative / avoid
Speculative
Scopolamine Amnesia Reversal · Aged Rat Cognitive Improvement · APP/PS1 Mouse Model · TBI Working Memory · Healthy Adult Cognitive Enhancement
Zero. No human clinical trial of Dihexa itself has been registered or completed. Fosgonimeton (the prodrug) has Phase 2 data showing failure on primary/secondary endpoints. The community uses Dihexa based entirely on rodent behavioral data and mechanistic claims — some of which carry a research integrity shadow.

Dihexa is the compound in this reference that best illustrates the difference between a compelling story and verified evidence. The story is extraordinary. The evidence has been specifically and formally damaged.

The central tension resolved: Washington State University developed an angiotensin IV-derived hexapeptide that, in preclinical studies from that lab, reversed experimental amnesia, improved spatial learning in aged rats, and demonstrated synaptogenesis in hippocampal cell cultures at concentrations reportedly 10 million times lower than BDNF. A PhD student from the lab became CEO of a company built on this science, which raised significant capital, renamed itself Athira Pharma, and took a prodrug into Phase 2/3 clinical trials for Alzheimer's disease. In 2021, the doctoral dissertation underlying the foundational mechanistic research was found to contain manipulated images. The CEO resigned. The stock dropped 67%. In 2025, the company paid $4 million to settle federal False Claims Act allegations. In 2023, the clinical prodrug failed Phase 2/3 on primary and secondary endpoints. The community continues to use Dihexa based on the behavioral rodent data (not directly implicated in the misconduct), limited independent replication (Sun 2021, 2025 biorXiv preprint), and the biological plausibility of the HGF/c-Met mechanism (well-supported in independent neuroscience literature). All of these pillars are real. They are also substantially weakened by the events of 2021-2025 in ways the community has not fully processed.

What Dihexa is not: the compound is not proven to be fraudulent — the behavioral data and some mechanistic findings may be perfectly valid. The misconduct was in the western blot images of the doctoral dissertation, not necessarily in every finding attributed to the lab or the compound. The independent replication exists. The HGF/c-Met background biology is solid. These are reasons why Dihexa remains worth understanding rather than simply dismissing.

What Dihexa is: a compound with real preclinical behavioral evidence, a compromised mechanistic foundation, a clinical prodrug that failed, a safety profile that is completely uncharacterized including a mechanism-real cancer concern from c-Met potentiation, and a community using it based on the most generous possible interpretation of a damaged evidence base.

Categories
Cognition & MoodLongevity & Anti-aging
Properties
Active malignancy: hard stopNot injectable
Evidence
CAnimal replicated
The Mechanism — What It Claims to Do
Dihexa allosterically facilitates HGF dimerization and binding to c-Met (the receptor tyrosine kinase). Activated c-Met triggers: PI3K/Akt (neuronal survival); Ras/MAPK/ERK (synaptic plasticity); Rac1/Cdc42 (cytoskeletal remodeling, dendritic spine formation). The downstream result: stimulated synaptogenesis (formation of new synaptic connections), increased dendritic spine density, enhanced LTP, and neuroprotection. The community's attraction: structural synaptogenesis rather than transient neurotransmitter modulation.
The '10 Million Times More Potent Than BDNF' Claim
WSU lab studies reported Dihexa to be up to 10 million times more potent than BDNF in cell culture synaptogenesis assays. This headline figure drove enormous community excitement. Critical context: (1) this is an in vitro potency comparison in a specific cell culture assay — not a comparison of clinical efficacy in human brains; (2) the doctoral research that generated much of this mechanistic data has been implicated in a research integrity investigation (see Section 4); (3) the specific potency figure should be treated with significant caution given the data integrity context.
THE RESEARCH INTEGRITY ISSUE — READ BEFORE ANYTHING ELSE
In 2021, it emerged that western blot images in the doctoral dissertation of Leen Kawas — the CEO of Athira Pharma (formerly M3 Biotechnology, the WSU spinout that developed Dihexa's clinical prodrug fosgonimeton) — appeared to have been manipulated. Kawas had been a PhD student in Harding's lab at WSU, where Dihexa was developed. She resigned as Athira CEO in October 2021. In January 2025, Athira settled False Claims Act allegations for over $4 million related to NIH grants referencing the compromised research. The western blot images implicated were part of the foundational HGF/c-Met mechanistic story. The behavioral data (water maze performance in rodents) was not directly implicated, but the mechanistic foundation supporting why those behaviors occur is now compromised.
The Clinical Translation — What Failed
Athira Pharma developed fosgonimeton (ATH-1017), a phosphate prodrug of the Dihexa metabolite, and ran it through LIFT-AD — a Phase 2/3 clinical trial in Alzheimer's patients. Results announced December 2023: fosgonimeton failed to meet primary or secondary endpoints. An apparent improvement in ADAS-Cog13 at 40 mg was difficult to interpret due to baseline group differences. Four of ten participants in the higher-dose arm dropped out due to adverse events. The failure of fosgonimeton does not directly disprove Dihexa's preclinical effects, but it raises serious questions about whether HGF/c-Met modulation produces meaningful cognitive benefits in humans.
What Remains of the Evidence
Behavioral data in rodents (scopolamine amnesia reversal, Morris Water Maze performance in aged rats) was not directly implicated in the data integrity findings. Sun et al. (Brain Sciences, 2021) — an independent Chinese group with no WSU affiliation — found Dihexa improved memory in APP/PS1 Alzheimer's model mice via PI3K/AKT signaling. A 2025 biorXiv preprint (independent, WSU-affiliated but different lab) showed Dihexa improved working memory after mild TBI in rats. These represent the surviving evidentiary pillars: behavioral animal data and limited independent replication.
Oral Bioavailability — The Notable Feature
Unlike most peptides in this reference, Dihexa is reported to have meaningful oral bioavailability and to cross the blood-brain barrier after oral administration. This is a significant practical advantage — no reconstitution, no injection. The BBB penetration is attributed to the compound's small size, lipophilicity from the hexanoic acid modification, and angiotensin IV's known CNS penetration properties. The pharmacokinetic characterization was part of the WSU research program and therefore shares some of the provenance concerns.
Community Dosing
Oral: 10-30 mg/day (commonly reported). Topical (transdermal): 10-50 mg/day applied to scalp or forearm (community-developed; no pharmacokinetic validation). Cycles typically 4-12 weeks. No validated human dose exists.
FDA / Regulatory
Not FDA-approved. Research chemical. Not a controlled substance. Athira Pharma holds patents related to fosgonimeton; the research chemical Dihexa itself is more patent-protected as a discovery than as a commercial product.
WADA
Not listed on the 2026 WADA Prohibited List. Not performance-enhancing in the athletic sense.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
Epitalon
C
Shared goal · cognition

40 Years of Research From One Lab. The Most Cited Telomere Peptide in the Longevity Space. The First Independent Replication Was Published in 2025.

Humanin
C
Shared goal · cognition

Found in Surviving Brain Cells of an Alzheimer's Patient. Encoded in Mitochondrial DNA. Higher in Centenarians' Children. Inversely Correlated With IGF-1. The GH Axis the Community Raises for Anti-Aging Suppresses It.

J-147
C
Shared goal · cognition

The Drug That Reversed Brain Aging in Mice. Discovered by Phenotypic Screen. Target Unknown for 7 Years. ATP Synthase: The Unexpected Bridge Between Alzheimer's and Aging. BDNF Induction. AMPK/mTOR via a Completely Novel Entry Point. Phase 1 Human Safety Trial Completed (NCT03838185). The Compound That Is Structurally Related to Curcumin But Pharmacologically Nothing Like It.

Check interactions